Abstract

Background  Vitamin K antagonists (VKAs) are associated with coronary artery calcification in low-risk populations, but their effect on calcification of large arteries remains uncertain. The effect of non–vitamin K antagonist oral anticoagulants (NOACs) on vascular calcification is unknown. We investigated the influence of use of VKA and NOAC on calcification of the aorta and aortic valve. Methods  In patients with atrial fibrillation without a history of major adverse cardiac or cerebrovascular events who underwent computed tomographic angiography, the presence of ascending aorta calcification (AsAC), descending aorta calcification (DAC), and aortic valve calcification (AVC) was determined. Confounders for VKA/NOAC treatment were identified and propensity score adjusted logistic regression explored the association between treatment and calcification (Agatston score > 0). AsAC, DAC, and AVC differences were assessed in propensity score–matched groups. Results  Of 236 patients (33% female, age: 58 ± 9 years), 71 (30%) used VKA (median duration: 122 weeks) and 79 (34%) used NOAC (median duration: 16 weeks). Propensity score–adjusted logistic regression revealed that use of VKA was significantly associated with AsAC (odds ratio [OR]: 2.31; 95% confidence interval [CI]: 1.16–4.59; p  = 0.017) and DAC (OR: 2.38; 95% CI: 1.22–4.67; p  = 0.012) and a trend in AVC (OR: 1.92; 95% CI: 0.98–3.80; p  = 0.059) compared with non-anticoagulation. This association was absent in NOAC versus non-anticoagulant (AsAC OR: 0.51; 95% CI: 0.21–1.21; p  = 0.127; DAC OR: 0.80; 95% CI: 0.36–1.76; p  = 0.577; AVC OR: 0.62; 95% CI: 0.27–1.40; p  = 0.248). A total of 178 patients were propensity score matched in three pairwise comparisons. Again, use of VKA was associated with DAC ( p  = 0.043) and a trend toward more AsAC ( p  = 0.059), while use of NOAC was not (AsAC p  = 0.264; DAC p  = 0.154; AVC p  = 0.280). Conclusion  This cross-sectional study shows that use of VKA seems to contribute to vascular calcification. The calcification effect was not observed in NOAC users.

Highlights

  • Vitamin K antagonists (VKAs) and non–vitamin K antagonist oral anticoagulants (NOACs) are widely prescribed drugs for prophylaxis and treatment of thromboembolic events

  • Propensity score–adjusted logistic regression revealed that use of VKA was significantly associated with ascending aorta calcification (AsAC) and descending aorta calcification (DAC) (OR: 2.38; 95% CI: 1.22–4.67; p 1⁄4 0.012) and a trend in aortic valve calcification (AVC) (OR: 1.92; 95% CI: 0.98–3.80; p 1⁄4 0.059) compared with non-anticoagulation

  • This association was absent in NOAC versus non-anticoagulant (AsAC OR: 0.51; 95% CI: 0.21–1.21; p 1⁄4 0.127; DAC OR: 0.80; 95% CI: 0.36–1.76; p 1⁄4 0.577; AVC OR: 0.62; 95% CI: 0.27– 1.40; p 1⁄4 0.248)

Read more

Summary

Introduction

Vitamin K antagonists (VKAs) and non–vitamin K antagonist oral anticoagulants (NOACs) are widely prescribed drugs for prophylaxis and treatment of thromboembolic events. VKAs exert their antithrombotic effect through interference with vitamin K metabolism, which is not limited to vitamin K–dependent coagulation factors, and all vitamin K–dependent proteins, including those involved in calcification.[1] Clinical studies confirm the association between VKA and vascular calcification.[2,3,4] Since vascular calcification is known to be a marker of increased cardiovascular morbidity and mortality,[5] VKA-induced calcification has become nonnegligible—certainly in initially low- to intermediate-risk populations This holds even more since current guidelines recommend oral anticoagulant (OAC) treatment even in lowrisk atrial fibrillation (AF) patients with only one stroke risk factor.[6]. We investigated the influence of use of VKA and NOAC on calcification of the aorta and aortic valve

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call